Key facts
- It has raised $8.7M; the latest was Later Stage VC ($4.5M) in Aug 2025.
- Notable investors include Fundomo, Formic Ventures, bpd partners, B3 Holding, BTCZ Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Sampling Human
- ·The full record, as it builds
Funding rounds
No funding rounds for Sampling Human are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sampling Human
Developer of a genetic analysis technology intended for complex single-cell data. The company's technology provides pre-symptomatic screening, personalized medicine, drug discovery, and basic science to solve problems in diagnostics and bioengineering, enabling physicians to translate a wealth of data into practical fields like diagnostics, and medicine.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Employees
- 19
- Website
- samplinghuman.com/
- Ownership
- Privately Held (backing)
Sampling Human doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sampling Human shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sampling Human in its N-PORT filings yet. We sweep new filings monthly.